A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs VAY 736 (Primary)
- Indications Pemphigus vulgaris
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 02 Apr 2018 Planned End Date changed from 13 Feb 2018 to 31 Jan 2019.
- 02 Apr 2018 Planned primary completion date changed from 13 Feb 2018 to 31 Jan 2019.
- 15 Mar 2018 This trial has been suspended in Austria.